MREO
NASDAQMereo BioPharma Group plc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks24+100%
2026-03-012026-08-23
Mix990d
- Other4(44%)
- SEC Filings4(44%)
- Analyst1(11%)
Latest news
25 items- ANALYSTMereo BioPharma downgraded by AnalystAnalyst downgraded Mereo BioPharma from Neutral to Underweight
- SECMereo BioPharma Group plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plcSCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
- SECSEC Form 10-Q filed by Mereo BioPharma Group plc10-Q - Mereo BioPharma Group plc (0001719714) (Filer)
- SECMereo BioPharma Group plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- PRMereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate HighlightsEntered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026 Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027 LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for t
- SECMereo BioPharma Group plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- PRSentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. salesCompanies will collaborate to refine the Phase 3 design during short option period SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026 /PRNewswire/ -- Sentynl Therapeutics, Inc. (
- PRMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. salesCompanies will collaborate to refine the Phase 3 design during short option period LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) --
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plcSCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
- SECSEC Form SCHEDULE 13G filed by Mereo BioPharma Group plcSCHEDULE 13G - Mereo BioPharma Group plc (0001719714) (Subject)
- SECMereo BioPharma Group plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- PR4basebio Announces Appointment of Chief Financial Officer and Board ChangesRichard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period. Richard is an accomplished leader with over 30 years' senior finance and strategic experience within
- SECAmendment: Mereo BioPharma Group plc filed SEC Form 8-K: Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K/A - Mereo BioPharma Group plc (0001719714) (Filer)
- SECSEC Form 10-Q filed by Mereo BioPharma Group plc10-Q - Mereo BioPharma Group plc (0001719714) (Filer)
- SECMereo BioPharma Group plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- PRMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesLONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments. "Based on extensive analysis of data across the two global Phase 3 studies of setrusumab in osteogenesis imperfecta in collaboration with our partner Ultragenyx, we believe there is basis to engage with the regulatory agencies to determine if there is a path forward in pediatric patients. These interactions have been initiated, and we plan to provide updates once we have some def
- SECSEC Form DEF 14A filed by Mereo BioPharma Group plcDEF 14A - Mereo BioPharma Group plc (0001719714) (Filer)
- SECSEC Form PRE 14A filed by Mereo BioPharma Group plcPRE 14A - Mereo BioPharma Group plc (0001719714) (Filer)
- SECMereo BioPharma Group plc filed SEC Form 8-K: Leadership Update8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- ANALYSTMereo BioPharma downgraded by AnalystAnalyst downgraded Mereo BioPharma from Overweight to Neutral
- SECSEC Form 10-K filed by Mereo BioPharma Group plc10-K - Mereo BioPharma Group plc (0001719714) (Filer)
- SECMereo BioPharma Group plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Mereo BioPharma Group plc (0001719714) (Filer)
- PRMereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate HighlightsAdditional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, March 19, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments. "In collaboration with our partner Ultragenyx, we have analysed a significant part of the data from the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperf
- INSIDERSEC Form 4 filed by Director Ekblom Anders4 - Mereo BioPharma Group plc (0001719714) (Issuer)
MREO FAQ
6 questionsWhat does Mereo BioPharma Group plc do?
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II...Where does MREO stock trade?
Mereo BioPharma Group plc (MREO) is listed on NASDAQ.What sector and industry is MREO in?
Mereo BioPharma Group plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MREO?
Mereo BioPharma Group plc has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight on 2026-08-19.What companies are similar to MREO?
Notable peers in the same industry include KNTE (Kinnate Biopharma Inc.), NMTR (9 Meters Biopharma Inc.), MTNB (Matinas Biopharma Holdings Inc.). Compare MREO side-by-side with any of them on Quantisnow.How can I track MREO on Quantisnow?
Quantisnow aggregates Mereo BioPharma Group plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MREO to receive live email and push alerts on every new disclosure.